GLP-1 Stocks: Who Wins the $100B Obesity Market

The GLP-1 market is projected to exceed $100 billion by 2030. Everyone knows that. What fewer people understand is that the competitive structure is shifting from “who has the best injectable” to “who has the first oral pill that works.” That transition is where the money is moving.

Novo Nordisk and Eli Lilly are the incumbents. Both are mega-caps. But the next wave of GLP-1 drugs, from Roche, Viking Therapeutics, and Structure Therapeutics, is attacking from different angles: dual agonists, triple agonists, and oral small molecules. Here are the five stocks that matter, ranked by pipeline depth, competitive position, and valuation. The ranking may surprise you.

1. Eli Lilly (LLY): The Undisputed Leader

LLY closed at $1,220.66 with a market cap of $1.07 trillion. That is not a typo. Lilly is the most valuable pharmaceutical company on earth, and GLP-1 drugs are why.

The franchise has three legs. Tirzepatide (Zepbound/Mounjaro) is the current market leader in injectable obesity care. Retatrutide, a triple GLP-1/GIP/glucagon agonist, delivered 22.6% weight loss at 80 weeks in TRIUMPH-3, a Phase 3 trial in 1,949 patients with severe obesity and cardiovascular disease. The BLA filing is expected in Q1 2027. Orforglipron (Foundayo), a once-daily oral GLP-1, is already FDA-approved for obesity after the ATTAIN trial showed 12.4% weight loss at 72 weeks. Lilly also reported ACHIEVE-3, a head-to-head Phase 3 trial where orforglipron 36 mg produced 9.2% weight loss versus 5.3% for oral semaglutide 14 mg, a 73.6% greater relative weight loss. Orforglipron is the first oral GLP-1 without food or water restrictions, which matters for adherence.

The bear case is valuation. At $1.07 trillion, Lilly trades at roughly 15x its 2025 revenue. That assumes the GLP-1 market grows as projected and Lilly maintains its 60% share. If oral GLP-1s cannibalize injectables faster than expected, or if competitors erode pricing, the multiple compresses. But Lilly has the most pipeline assets in or past Phase 2, the most approved products, and the best clinical data across every modality. It is the safest hold in the group and the most expensive.

2. Novo Nordisk (NVO): Chasing from Behind

NVO closed at $50.96 with a market cap of $220 billion. Novo built this market with semaglutide (Wegovy/Ozempic), but the narrative is deteriorating on three fronts.

First, CagriSema. The REDEFINE-1 trial showed 22.7% weight loss in non-diabetic patients at 68 weeks, which sounds competitive until you notice that Novo internally targeted 25%. The miss against internal expectations spooked the stock. CagriSema still beat semaglutide alone in REIMAGINE-2, with 14.2% weight loss versus 10.2% for semaglutide 2.4 mg in type 2 diabetes patients (p<0.0001). Novo plans to file for FDA approval in early 2026, with a decision expected in Q4 2026. REDEFINE-3, the cardiovascular outcomes trial, is ongoing with results expected in 2027 (NCT05669755).

Second, the EVOKE failure. Oral semaglutide failed to beat placebo in Phase 3 Alzheimer’s disease trials. The extension period was discontinued. This was always a long-shot optionality play, but its failure removes a pipeline narrative that some investors were pricing in.

Third, the Novo-Lilly lawsuit over GLP-1 advertising. This is a sideshow. Lawsuits between pharma giants over ad claims resolve slowly and change nothing about the competitive dynamics.

At $220 billion, NVO trades at roughly 8x its 2025 revenue. That is cheaper than Lilly, but the discount is earned. Novo has one approved franchise (semaglutide), one pending filing (CagriSema), and nothing in the oral small-molecule space. The pipeline is thinner than the market cap suggests.

3. Structure Therapeutics (GPCR): The Oral Sleeper

GPCR closed at $47.89 with a market cap of $3.5 billion. This is the stock the market is underrating.

Aleniglipron (GSBR-1290) is an oral small-molecule GLP-1 agonist. The Phase 2 ACCESS II trial showed 16.3% placebo-adjusted weight loss at the 180 mg dose at 44 weeks, with no evidence of a weight loss plateau. The open-label extension showed continued weight loss up to 16.2% at 56 weeks. That is the highest weight loss reported for any oral GLP-1, and it approaches injectable-level efficacy.

Compare that to orforglipron, which delivered 12.4% weight loss in the ATTAIN trial. Aleniglipron’s 16.3% is 31% better on a relative basis. If that holds in Phase 3, Structure has a best-in-class oral GLP-1. The company is preparing for Phase 3.

The risk is obvious. Phase 2 data does not guarantee Phase 3 success. The ACCESS II trial enrolled fewer than 200 patients per arm. A 44-week trial does not answer long-term safety questions. And Lilly, with its trillion-dollar market cap, can outspend Structure on commercialization by 300x.

At $3.5 billion market cap, GPCR is pricing in moderate Phase 3 success. If aleniglipron replicates Phase 2 data in Phase 3, the stock doubles or triples. If it misses, the stock loses 60%. That is the binary.

4. Viking Therapeutics (VKTX): The Dual Agonist Bet

VKTX closed at $33.86 with a market cap of $4.0 billion. Viking’s VK2735 is a dual GLP-1/GIP agonist, the same mechanism as Lilly’s tirzepatide. The Phase 2 VENTURE trial showed up to 14.7% weight loss at 13 weeks, with no plateau observed. That is strong for a 13-week trial, but it is also early.

The problem is that Viking is competing directly with Lilly’s tirzepatide, which is already approved and generating revenue. VK2735 has not started Phase 3. The company has not filed an NDA. By the time VK2735 reaches market, if it does, Lilly will have had years of commercial dominance and retatrutide approved as well.

Viking’s bull case is that VK2735 may offer differentiation in dosing or tolerability. The 14.7% weight loss at 13 weeks suggests a faster onset of action than tirzepatide. But Phase 2 data at 13 weeks tells you nothing about 72-week durability, which is what the FDA requires for obesity approval.

At $4.0 billion, VKTX is pricing in Phase 3 success. Do not pay that price for a pre-Phase 3 asset competing against an approved incumbent with a trillion-dollar market cap. The risk-reward is unfavorable.

5. Roche (RHHBY): The Dark Horse with a Manufacturing Problem

RHHBY closed at $56.52. This is an OTC ADR with low US trading volume (5,563 trades per day versus 107,951 for LLY). The data is valid, but the stock is not easily investable for most US investors. Roche’s primary listing is on the Swiss Exchange.

Roche’s enicepatide (CT-388) is a dual GLP-1/GIP agonist that achieved 22.5% placebo-adjusted weight loss at 48 weeks in Phase 2, without a plateau. That is competitive with Lilly’s retatrutide. More than 25% of patients achieved 30% weight loss. The Phase 3 program is starting in 2026, with a potential submission in 2028 and launch in 2029.

Roche cut the Carmot asset acmopatide to concentrate resources on enicepatide. That was the right call. Enicepatide is the better molecule. But Roche is three years behind Lilly and two years behind Novo in this market. By 2029, the injectable GLP-1 market will be saturated, and oral agents will be the growth vector.

The investable question is whether Roche can use its global commercial infrastructure to compete in a market that Lilly and Novo already dominate. At a $230 billion parent-company market cap, enicepatide is a rounding error for Roche’s valuation. The catalyst is real, but the investable US pure play does not exist.

Risks

The sector risk is pricing. GLP-1 drugs cost $1,000 to $1,300 per month. Payers are pushing back. Medicare coverage for obesity was expanded, but prior authorization requirements are tightening. If ASPs compress 20% as competition increases, every company in this group loses revenue projections.

The pipeline risk is the oral versus injectable transition. Oral GLP-1s produce 12% to 16% weight loss. Injectables produce 20% to 25%. If patients and doctors prioritize efficacy over convenience, oral GLP-1s become a second-line therapy. That caps the upside for Structure Therapeutics and Lilly’s orforglipron franchise.

The competitive risk is manufacturing. GLP-1 drugs require peptide synthesis at industrial scale. Lilly and Novo have spent billions building capacity. Roche, Viking, and Structure have not. A company with great data but no manufacturing capacity is a license target, not a standalone commercial success.

Ranking

1. LLY is the safest hold. Trillion-dollar market cap, three approved or near-approved GLP-1s, the most pipeline assets in or past Phase 2. The valuation is full but the moat is real. How to invest in biotech starts with understanding market position, and Lilly’s position is unassailable for the next three years.
2. GPCR is the best risk-reward. $3.5 billion market cap, best-in-class oral Phase 2 data, Phase 3 starting. The binary is clear: Phase 3 success doubles the stock, failure halves it.
3. NVO is a hold with deteriorating narrative. CagriSema is the catalyst, but the EVOKE failure and thinner pipeline make this a value trap at $220 billion.
4. VKTX is too expensive for pre-Phase 3. The data is good but the competitive position is weak. Wait for Phase 3 design before buying.
5. RHHBY is a real drug with no investable US pure play. The catalyst exists but the ADR is too illiquid for most portfolios.

The PDUFA date to watch is CagriSema’s Q4 2026 FDA decision. If CagriSema gets approved with competitive weight loss data, Novo closes the gap with Lilly. If the label is narrow or the data is underwhelming, Lilly’s dominance extends. Novo is also diversifying beyond GLP-1 with its hemophilia franchise, which matters if the obesity narrative continues to compress.